|
NCOA6 |
nuclear receptor coactivator 6 |
- RORA activates gene expression
- BMAL1:CLOCK,NPAS2 activates circadian gene expression
- PPARA activates gene expression
- PPARA activates gene expression
- Transcriptional activation of mitochondrial biogenesis
- Activation of gene expression by SREBF (SREBP)
- Transcriptional regulation of white adipocyte differentiation
- Regulation of lipid metabolism by PPARalpha
- Circadian Clock
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
|
|
|
|
NEDD4 |
NEDD4 E3 ubiquitin protein ligase |
- ISG15 antiviral mechanism
- Downregulation of ERBB4 signaling
- Regulation of PTEN localization
- Regulation of PTEN stability and activity
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
NFKBIA |
NFKB inhibitor alpha |
- Activation of NF-kappaB in B cells
- RIP-mediated NFkB activation via ZBP1
- Downstream TCR signaling
- NF-kB is activated and signals survival
- FCERI mediated NF-kB activation
- TAK1 activates NFkB by phosphorylation and activation of IKKs complex
- SUMOylation of immune response proteins
- IkBA variant leads to EDA-ID
- CLEC7A (Dectin-1) signaling
- Ub-specific processing proteases
- Interleukin-1 signaling
- TRAF6 mediated NF-kB activation
|
- Acetylsalicylic acid
- Bardoxolone methyl
- Astaxanthin
|
- Ectodermal dysplasia associated immunodeficiency (EDA-ID), including the following two diseases: NF-kappa-B essential modulator (NEMO) defect; Inhibitor of kappa-B (I-kappa-B) defect
- Hodgkin lymphoma
|
|
NMT1 |
N-myristoyltransferase 1 |
- Late Phase of HIV Life Cycle
- Inactivation, recovery and regulation of the phototransduction cascade
- Activation, myristolyation of BID and translocation to mitochondria
|
- (1-Methyl-1h-Imidazol-2-Yl)-(3-Methyl-4-{3-[(Pyridin-3-Ylmethyl)-Amino]-Propoxy}-Benzofuran-2-Yl)-Methanone
|
|
|
NOS2 |
nitric oxide synthase 2 |
- ROS and RNS production in phagocytes
- Nitric oxide stimulates guanylate cyclase
- Interleukin-4 and Interleukin-13 signaling
- Peroxisomal protein import
- Peroxisomal protein import
- Inhibition of nitric oxide production
|
- Arginine
- Citrulline
- Minocycline
- Miconazole
- Dexamethasone
- N,N-dimethylarginine
- 4R-Fluoro-N6-ethanimidoyl-L-lysine
- 3-Bromo-7-Nitroindazole
- N-[3-(aminomethyl)benzyl]acetamidine
- 7-Nitroindazole
- S-Ethylisothiourea
- Thiocoumarin
- N-omega-propyl-L-arginine
- 6-Nitroindazole
- N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine
- Imidazole
- N-(4-{2-[(3-chlorobenzyl)amino]ethyl}phenyl)thiophene-2-carboximidamide
- Thiocitrulline
- L-erythro-7,8-dihydrobiopterin
- 5-Nitroindazole
- KD7040
- Fenoxaprop-ethyl
- Pimagedine
- 5-(4'-AMINO-1'-ETHYL-5',8'-DIFLUORO-1'H-SPIRO[PIPERIDINE-4,2'-QUINAZOLINE]-1-YLCARBONYL)PICOLINONITRILE
- N-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-1-[2-(1H-IMIDAZOL-1-YL)-6-METHYLPYRIMIDIN-4-YL]-D-PROLINAMIDE
- 4-({4-[(4-methoxypyridin-2-yl)amino]piperidin-1-yl}carbonyl)benzonitrile
- (2S)-2-methyl-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine
- (3R)-3-[(1,2,3,4-tetrahydroisoquinolin-7-yloxy)methyl]-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine
- 4-(1,3-BENZODIOXOL-5-YLOXY)-2-[4-(1H-IMIDAZOL-1-YL)PHENOXY]PYRIMIDINE
- (3S)-1-(1,3-BENZODIOXOL-5-YLMETHYL)-3-[4-(1H-IMIDAZOL-1-YL)PHENOXY]PIPERIDINE
- 4-(1,3-BENZODIOXOL-5-YLOXY)-2-[4-(1H-IMIDAZOL-1-YL)PHENOXY]-6-METHYLPYRIMIDINE
- ETHYL 4-[(4-CHLOROPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE
- N-[2-(4-AMINO-5,8-DIFLUORO-1,2-DIHYDROQUINAZOLIN-2-YL)ETHYL]-3-FURAMIDE
- ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE
- N-[2-(6-AMINO-4-METHYLPYRIDIN-2-YL)ETHYL]-4-CYANOBENZAMIDE
- 1-(6-CYANO-3-PYRIDYLCARBONYL)-5',8'-DIFLUOROSPIRO[PIPERIDINE-4,2'(1'H)-QUINAZOLINE]-4'-AMINE
- 4-(1H-IMIDAZOL-1-YL)PHENOL
- 1-[4-(AMINOMETHYL)BENZOYL]-5'-FLUORO-1'H-SPIRO[PIPERIDINE-4,2'-QUINAZOLIN]-4'-AMINE
- Triflusal
- Levamlodipine
- Dipyrithione
- Dexamethasone acetate
|
|
|
NPHS1 |
NPHS1 adhesion molecule, nephrin |
- Nephrin family interactions
- Nephrin family interactions
|
|
- Nephrotic syndrome and focal segmental glomerulosclerosis
|
|
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
|
- Vitamin E
- Oxiconazole
- Phenytoin
- Diethylstilbestrol
- Clotrimazole
- Pentobarbital
- Spironolactone
- Lindane
- Flutamide
- Ritonavir
- Erlotinib
- Cyclophosphamide
- Mephenytoin
- Carbamazepine
- Tamoxifen
- Warfarin
- Ethotoin
- Estradiol
- Mifepristone
- Methylphenobarbital
- Ethinylestradiol
- Ketoconazole
- Fenofibrate
- Rifampicin
- Clonazepam
- Miconazole
- Nifedipine
- Econazole
- Sulfinpyrazone
- Phenobarbital
- Ifosfamide
- Rifaximin
- Paclitaxel
- Dexamethasone
- Docetaxel
- Bezafibrate
- Genistein
- Prasterone
- Hyperforin
- Resveratrol
- Pregnenolone
- Quercetin
- SR12813
- Afimoxifene
- Phenolphthalein
- Permethrin
- Dovitinib
- Chenodeoxycholic acid
- TO-901317
- Hexestrol
- Triclosan
- Rilpivirine
- Pyrethrum extract
- Myrrh
- Piperine
- Troleandomycin
- Fenofibric acid
- Estradiol acetate
- Estradiol benzoate
- Estradiol cypionate
- Estradiol dienanthate
- Estradiol valerate
- alpha-Tocopherol succinate
- D-alpha-Tocopherol acetate
- Dexamethasone acetate
|
|
|
NR1I3 |
nuclear receptor subfamily 1 group I member 3 |
|
- Doxylamine
- Meclizine
- Loperamide
- Ketoconazole
- Atorvastatin
- Pheniramine
- Prasterone
- 16,17-Androstene-3-Ol
- Resveratrol
- Cholesterol
- Phenolphthalein
- 3,20-Pregnanedione
- Hexestrol
- Triclosan
|
|
|
NR3C1 |
nuclear receptor subfamily 3 group C member 1 |
- HSP90 chaperone cycle for steroid hormone receptors (SHR)
- Circadian Clock
- SUMOylation of intracellular receptors
- PTK6 Expression
- Regulation of RUNX2 expression and activity
- FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
- Potential therapeutics for SARS
|
- Flunisolide
- Diflorasone
- Alclometasone
- Medrysone
- Amcinonide
- Fluorometholone
- Megestrol acetate
- Levonorgestrel
- Beclomethasone dipropionate
- Progesterone
- Spironolactone
- Betamethasone
- Desoximetasone
- Fluticasone propionate
- Fluocinolone acetonide
- Ulobetasol
- Triamcinolone
- Prednisone
- Flumethasone
- Fludrocortisone
- Norethisterone
- Hydrocortisone
- Mometasone
- Hydrocortamate
- Mifepristone
- Clocortolone
- Flurandrenolide
- Prednisolone
- Loteprednol etabonate
- Rimexolone
- Methylprednisolone
- Clobetasol propionate
- Fluocinonide
- Prednicarbate
- Fluoxymesterone
- Budesonide
- Dexamethasone
- Desonide
- Cortisone acetate
- Paramethasone
- Drospirenone
- Ciclesonide
- Hexane-1,6-Diol
- Aldosterone
- ORG-34517
- Difluprednate
- Ulipristal
- Fluticasone furoate
- Tixocortol
- Difluocortolone
- Gestrinone
- Deflazacort
- Onapristone
- Cortivazol
- Clobetasone
- Fluticasone
- Mometasone furoate
- Hydrocortisone aceponate
- Hydrocortisone acetate
- Hydrocortisone butyrate
- Hydrocortisone cypionate
- Hydrocortisone phosphate
- Hydrocortisone probutate
- Hydrocortisone valerate
- Segesterone acetate
- Prednisolone phosphate
- Dexamethasone acetate
- Betamethasone phosphate
- Prednisolone acetate
|
- 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency
|
|
P2RY2 |
purinergic receptor P2Y2 |
- G alpha (q) signalling events
- P2Y receptors
- Surfactant metabolism
|
- Promethazine
- Suramin
- Denufosol
- INS 316
|
|
|
PAK2 |
p21 (RAC1) activated kinase 2 |
- Nef and signal transduction
- Generation of second messenger molecules
- Regulation of PAK-2p34 activity by PS-GAP/RHG10
- Regulation of activated PAK-2p34 by proteasome mediated degradation
- Stimulation of the cell death response by PAK-2p34
- FCERI mediated MAPK activation
- FCERI mediated MAPK activation
- CD28 dependent Vav1 pathway
- Ephrin signaling
- Sema3A PAK dependent Axon repulsion
- Activation of RAC1
- VEGFA-VEGFR2 Pathway
- Smooth Muscle Contraction
- VEGFR2 mediated vascular permeability
- CD209 (DC-SIGN) signaling
- RHO GTPases activate PAKs
- RHO GTPases activate PAKs
- MAPK6/MAPK4 signaling
- Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
|
|
|
|
PDCD6IP |
programmed cell death 6 interacting protein |
- Budding and maturation of HIV virion
- Uptake and function of anthrax toxins
- RIPK1-mediated regulated necrosis
- Regulation of necroptotic cell death
|
|
|
|
PDE4D |
phosphodiesterase 4D |
- DARPP-32 events
- G alpha (s) signalling events
|
- Adenosine phosphate
- Caffeine
- Caffeine
- Dyphylline
- Iloprost
- Amrinone
- Roflumilast
- Piclamilast
- Rolipram
- 3,5-Dimethyl-1-(3-Nitrophenyl)-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
- 2-[3-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Propylamino]-2-Hydroxymethyl-Propane-1,3-Diol
- Zardaverine
- 1-(4-Aminophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
- (S)-Rolipram
- Cilomilast
- (R)-Rolipram
- 3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
- 1-(4-Methoxyphenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester
- Crisaborole
- Ibudilast
- Tetomilast
- Exisulind
- (4R)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one
- 3,5-DIMETHYL-1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
- 3-isobutyl-1-methyl-7H-xanthine
- 4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid
- Trapidil
|
|
|
PDE6G |
phosphodiesterase 6G |
- Activation of the phototransduction cascade
- Activation of the phototransduction cascade
- Inactivation, recovery and regulation of the phototransduction cascade
- Ca2+ pathway
- Ca2+ pathway
|
- Sildenafil
- Vardenafil
- 3-isobutyl-1-methyl-7H-xanthine
|
- Retinitis pigmentosa (RP)
|
|
PDGFRB |
platelet derived growth factor receptor beta |
- PIP3 activates AKT signaling
- Downstream signal transduction
- Signaling by PDGF
- Constitutive Signaling by Aberrant PI3K in Cancer
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
|
- Becaplermin
- Sorafenib
- Imatinib
- Dasatinib
- Sunitinib
- XL999
- XL820
- Pazopanib
- Midostaurin
- Regorafenib
- Nintedanib
- Polaprezinc
- Trapidil
- Foreskin fibroblast (neonatal)
- Fostamatinib
- Erdafitinib
- Pexidartinib
- Ripretinib
- Pralsetinib
|
|
|
PDPK1 |
3-phosphoinositide dependent protein kinase 1 |
- GPVI-mediated activation cascade
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Activation of AKT2
- Downstream TCR signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- FCERI mediated NF-kB activation
- Integrin signaling
- CD28 dependent PI3K/Akt signaling
- G beta:gamma signalling through PI3Kgamma
- RSK activation
- VEGFR2 mediated vascular permeability
- VEGFR2 mediated cell proliferation
- CLEC7A (Dectin-1) signaling
- RHO GTPases activate PKNs
- Constitutive Signaling by AKT1 E17K in Cancer
- Regulation of TP53 Degradation
- Estrogen-stimulated signaling through PRKCZ
- Estrogen-stimulated signaling through PRKCZ
|
- Celecoxib
- Inositol 1,3,4,5-Tetrakisphosphate
- 7-Hydroxystaurosporine
- Bisindolylmaleimide VIII
- Staurosporine
- Bisindolylmaleimide I
- Dexfosfoserine
- 10,11-dimethoxy-4-methyldibenzo[c,f]-2,7-naphthyridine-3,6-diamine
- 5-HYDROXY-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-2-ONE
- 1-{2-OXO-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-5-YL}UREA
- 2-(1H-imidazol-1-yl)-9-methoxy-8-(2-methoxyethoxy)benzo[c][2,7]naphthyridin-4-amine
- 3-(1H-indol-3-yl)-4-(1-{2-[(2S)-1-methylpyrrolidinyl]ethyl}-1H-indol-3-yl)-1H-pyrrole-2,5-dione
- 3-[1-(3-AMINOPROPYL)-1H-INDOL-3-YL]-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE
- Fostamatinib
|
|
|
PECAM1 |
platelet and endothelial cell adhesion molecule 1 |
- Platelet degranulation
- Cell surface interactions at the vascular wall
- PECAM1 interactions
- Integrin cell surface interactions
- Platelet sensitization by LDL
- Neutrophil degranulation
|
|
|
|
PELP1 |
proline, glutamate and leucine rich protein 1 |
- Major pathway of rRNA processing in the nucleolus and cytosol
- PTK6 Expression
|
|
|
|
PGR |
progesterone receptor |
- Nuclear signaling by ERBB4
- HSP90 chaperone cycle for steroid hormone receptors (SHR)
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
- Estrogen-dependent gene expression
|
- Etonogestrel
- Desogestrel
- Megestrol acetate
- Levonorgestrel
- Dydrogesterone
- Progesterone
- Spironolactone
- Lindane
- Fluticasone propionate
- Medroxyprogesterone acetate
- Mitotane
- Norethisterone
- Mometasone
- Ethynodiol diacetate
- Mifepristone
- Norgestimate
- Drospirenone
- Danazol
- Oxybenzone
- Allylestrenol
- Phthalic Acid
- Metribolone
- Tanaproget
- Telapristone acetate
- Asoprisnil
- Norelgestromin
- Gestodene
- Hydroxyprogesterone caproate
- Ulipristal
- Fluticasone furoate
- Dienogest
- Medrogestone
- Norgestrel
- Homosalate
- Enzacamene
- Gestrinone
- Darolutamide
- Demegestone
- Fluticasone
- Mometasone furoate
- Segesterone acetate
|
|
|
PIK3R1 |
phosphoinositide-3-kinase regulatory subunit 1 |
- PI3K Cascade
- IRS-mediated signalling
- GPVI-mediated activation cascade
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- PI3K events in ERBB4 signaling
- PIP3 activates AKT signaling
- Interleukin-7 signaling
- Interleukin-7 signaling
- Signaling by SCF-KIT
- Synthesis of PIPs at the plasma membrane
- GAB1 signalosome
- Signaling by cytosolic FGFR1 fusion mutants
- Downstream signal transduction
- PI3K events in ERBB2 signaling
- PI3K/AKT activation
- Downstream TCR signaling
- Role of phospholipids in phagocytosis
- Tie2 Signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- DAP12 signaling
- Role of LAT2/NTAL/LAB on calcium mobilization
- Nephrin family interactions
- Costimulation by the CD28 family
- CD28 dependent PI3K/Akt signaling
- G alpha (q) signalling events
- GP1b-IX-V activation signalling
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Constitutive Signaling by EGFRvIII
- PI-3K cascade:FGFR1
- PI-3K cascade:FGFR2
- PI-3K cascade:FGFR3
- PI-3K cascade:FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- RAF/MAP kinase cascade
- Interleukin-4 and Interleukin-13 signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PI3K/AKT signaling
- Signaling by FGFR3 fusions in cancer
- Signaling by FGFR3 point mutants in cancer
- RET signaling
- Extra-nuclear estrogen signaling
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Activated NTRK2 signals through PI3K
- Interleukin receptor SHC signaling
- Regulation of signaling by CBL
- Regulation of signaling by CBL
- Activated NTRK3 signals through PI3K
- FLT3 Signaling
- FLT3 Signaling
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 ITD and TKD mutants
- Signaling by FLT3 ITD and TKD mutants
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
- Isoprenaline
- SF1126
- Enzastaurin
- Wortmannin
|
|